Screener
Acadia Pharmaceuticals ACAD Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from issuance of common stock, net of issuance costs | 14,725 | 17,794 |
| Net cash provided by financing activities | 14,725 | 17,794 |
| Effect of exchange rate changes on cash | 52 | 19 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 207,291 | (65,251) |
| Cash, cash equivalents and restricted cash | ||
| Beginning of period | 185,540 | 328,359 |
| End of period | $392,831 | $263,108 |
| Supplemental disclosure of noncash information: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's net change in cash?
- Acadia Pharmaceuticals (ACAD) reported net change in cash of $102.77M in Q2 2026.
- What is the long-term trend for Acadia Pharmaceuticals's net change in cash?
- Over 2 years (2022 to 2024), Acadia Pharmaceuticals's net change in cash has grown at a 102.7% compound annual growth rate (CAGR), from -$32.59M to $133.93M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Acadia Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude